MedTrace Logo

Feasibility Pilot Exploring Variability in Biomarkers and PROs in AML

NCT04908852 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2023-04-05

No results posted yet for this study

Summary

This research study is being conducted to help understand how the symptoms during treatment for acute myeloid leukemia (AML) may be affected by metabolism and how best to study this association. Symptoms include experiences like fatigue, sleep disturbance, pain, and depression.

Conditions

  • Acute Myeloid Leukemia (AML)

Interventions

OTHER

Blood Sample Collection - Observational Study

Blood samples will be collected at enrollment and week 4 and used in analyses to understand associations between metabolic function and symptom experiences.

OTHER

Symptom questionnaires - Observational Study

Symptom questionnaires at baseline, 1-, 2-, 3- and 4-weeks.

Sponsors & Collaborators

Principal Investigators

  • Marilyn J. Hammer, PhD, RN · Dana-Farber Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2023-02-23
Completion
2023-02-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04908852 on ClinicalTrials.gov